Alethia Young
William Blair is expanding its equities platform with new senior hires in biotech equity research and institutional sales and trading as the firm increases investment in areas tied to growing client demand and evolving institutional trading strategies.
The Chicago-based financial services firm said the additions are part of a broader effort to strengthen research coverage and deepen expertise across specialized sectors, particularly biotechnology and multi-strategy equities trading.
As part of the expansion, Alethia Young has joined the firm’s biotech equity research team. William Blair said the hire reflects its continued investment in biotechnology research, an area that has drawn heightened investor interest amid sustained innovation in drug development, precision medicine and emerging therapeutic platforms.
Young brings roughly 25 years of experience spanning biotechnology operations, finance and sell-side research. Before joining William Blair, she served as chief financial officer at Bicycle Therapeutics, a biotechnology company focused on developing Bicycle-based medicines.
Earlier in her career, Young worked as a biotechnology equity research analyst at Cantor Fitzgerald, Credit Suisse and Deutsche Bank. Her experience also includes serving as an independent board member within the healthcare sector. She earned a degree in economics from Duke University.
Director of Equity Research John Kreger said biotechnology remains an increasingly important area for institutional investors and described the hire as part of a targeted strategy to expand differentiated sector analysis and research capabilities.
In a separate move, the firm also appointed Cody McGrath as managing director and head of multi-strategy sales. The position is designed to support institutional clients pursuing more sophisticated and diversified trading strategies across the equities market.
McGrath joins William Blair from Seaport Research Partners, where he helped expand the firm’s multi-strategy client business. Prior to that, he spent nearly 14 years at Stephens Inc. and also held positions at SMBC Nikko Securities America and JPMorgan Chase & Co..
Head of Equities Scott McLaughlin said the latest appointments align with William Blair’s strategy of expanding expertise in areas where institutional investors increasingly value specialized market insight and long-term advisory relationships.
The hires come as investment firms across Wall Street continue increasing resources in healthcare research, alternative investment strategies and institutional trading capabilities amid shifting market conditions and growing demand for sector-specific analysis.
Founded as an independent and employee-owned financial services partnership, William Blair operates across investment banking, investment management and private wealth management businesses with offices in more than 30 locations globally.
Leave a comment